Política de cookies

Utilizamos cookies propias y de terceros para mejorar nuestros servicios y mostrarle publicidad relacionada con sus preferencias mediante el análisis de sus hábitos de navegación. Si continua navegando, consideramos que acepta su uso.

Más información
Permissions Requests - Help - - Sign up - Phone number 902 888 740

2016 FI

© Thomson Reuters, Journal Citation Reports, 2016

Indexed in:

Index Medicus/Medline, Excerpta Medica/EMBASE, IBECS, IME Cancerlit, Bibliomed, CabHealth, Scisearch, HealthStar, Scopus, Prous, Science Intergews, Science Citation Index Expanded.


  • Impact Factor: 1.439 (2016)
  • CiteScore 2017: 1.24
    Read more
  • SCImago Journal Rank (SJR):0,504
  • Source Normalized Impact per Paper (SNIP):0,791

© Thomson Reuters, Journal Citation Reports, 2017

Allergol Immunopathol (Madr) 2016;44:138-48 - DOI: 10.1016/j.aller.2015.05.006
Original Article
The efficacy of single-high dose inhaled corticosteroid versus oral prednisone treatment on exhaled leukotriene and 8-isoprostane levels in mild to moderate asthmatic children with asthma exacerbation
O. Keskina,, , , U. Ulucab, M. Keskinb, B. Gogebakanc, E. Kucukosmanoglua, M.Y. Ozkarsa, S. Kuld, H. Bayramc, Y. Coskunb
a Department of Pediatric Allergy and Immunology, Gaziantep University School of Medicine, Gaziantep, Turkey
b Department of Pediatrics, Gaziantep University School of Medicine, Gaziantep, Turkey
c Department of Pulmonology, Gaziantep University School of Medicine, Gaziantep, Turkey
d Department of Biostatistics, Gaziantep University School of Medicine, Gaziantep, Turkey
Received 06 February 2015, Accepted 07 May 2015

The anti-inflammatory effect of high-dose inhaled corticosteroids (ICS) in children with asthma exacerbation is unknown. We aimed to investigate the efficacy of single-high dose ICS versus oral prednisone treatment followed by a course of six day high-dose ICS or oral prednisone (P) treatment on the concentrations of Cys-LTs and 8-isoprostane levels in the exhaled breath condensate (EBC) of children with asthma exacerbation.


Ninety-four children with moderate–severe asthma exacerbation were evaluated with asthma scores, peak expiratory flow rate (PEF), forced expiratory volume in first second (FEV1) and exhaled Cys-LT and 8-isoprostane levels before and after treatment. EBC was collected from 52 patients before and four hours after treatment with inhaled fluticasone propionate (FP) (4000μg) or P and after six days of treatment with FP-1000μg/day or P. Cys-LTs and 8-isoprostane concentrations were determined using a specific immunoassay kit.


Both single high-dose FP (n=59) and p (n=35) treatment resulted in a significant improvement in asthma score (p<0.0001), PEF (p<0.0001), and FEV1 (p<0.0001). Cys-LT concentration in the EBC decreased significantly both after the initial treatment (p=0.001), and at the end of the six-day period in the FP group (p<0.0001). 8-Isoprostane concentration was lower only after six days of treatment with FP-1000μg/day in the FP group (p=0.023). There was a significant decrease in exhaled Cys-LTs after four hours (p=0.012) and six days of P treatment (p=0.018) in children with asthma exacerbation.


High-dose ICS treatment may be useful in the treatment of children with asthma exacerbation. The effects start as early as after four hours. The suppression of Cys-LTs production contributes to the early effects. Suppression of both Cys-LTs and oxidants may favourably contribute to the effects observed later.

Download PDF


Read the complete contents of this article

Already registered?